Login to Your Account

BI Builds First Mammalian Cell CMO Facility in China

By Shannon Ellis
Contributing Writer

Wednesday, July 3, 2013
SHANGHAI – Looking to create synergies between its own expertise and growing pool of small and medium biotech ventures in China, Boehringer Ingelheim Pharmaceuticals GmbH (BI) plans to build the first international biopharma contract manufacturing facility (CMO) in the country with mammalian cell technology.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription